

CLINICAL RESEARCH NEWSLETTER

DECEMBER 2025
 VOLUME 1 | ISSUE 9

CORE Fundamentals Training



The CORE Research Fundamentals Training Program equips clinical research professionals with the essential knowledge and tools to conduct high-quality cancer clinical trials across the Georgia NCORP



12-13 JANUARY 2026
 AT 9:00AM - 4:00 PM

What You'll Learn:

- Cancer Basics 101
- Clinical Trials 101
- Research Roles & Responsibilities
- Informed Consent Process & Documentation
- Regulatory Compliance
- Eligibility Screening & Enrollment
- Safety Reporting (AEs, SAEs, UPs)
- Protocol Interpretation & Compliance
- Good Documentation Practices

Upon completion of this class, you will receive CEU Credits!

CONTACT US

404-523-8735 ext. 4 www.georgiacancerinfo.org

Kudos

Kudos to Sites SC117, GA031 and GA134, GA024 for their enrollment efforts for DCP-001.

Also, site GA031 for LUNGMAP and WF2304-A172401.

Way to go!

Reminders

Georgia CORE's office will be closed starting December 22, 2025 until January 2, 2026 and will reopen Monday, January 5, 2026.

For Urgent questions, you can reach out to Kaylan Dixon at kdixon@georgiacore.org

Inside this issue

TOPIC	PAGE
CORE Fundamentals/ Kudos/News	1
Enrolling CCDR Trials	2
Recently Opened GA NCORP Trials	3
Study Spotlight/Fundamentals Class	4
Upcoming Meetings & Kudos	5
Test Your Knowledge Quiz	6

Contact Info

GA NCORP CCDR Program
 Stephanie Reyes, RN, MSN, OCN (while Alaina Newsome is OOO)
smiths1@sjchs.org

CLINICAL RESEARCH

NEWSLETTER

DECEMBER 2025
 VOLUME 1 | ISSUE 9

ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) <i>Deemed high priority by the Executive Committee.</i>	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) <i>Sites must receive approval prior to initiating any study start-up activities.</i>	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR <i>Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.</i>	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/23/2024
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

CLINICAL RESEARCH

NEWSLETTER

DECEMBER 2025
 VOLUME 1 | ISSUE 9

Recently Activated and Recommended Trials¹

Research Base	Title	CTSU Activation Date
SWOG	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	10/22/2025
URCC	URCC-24060: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment	9/30/2025
ECOG	EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer	10/23/2025
	EA1241: Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol	12/4/2025
Wake Forest	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/02/2025
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

CLINICAL RESEARCH NEWSLETTER

DECEMBER 2025
 VOLUME 1 | ISSUE 9

CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS PENDING ACTIVATION

Research Base	Title	Description
ALLIANCE	A232402CD: PAGODA Randomized Trial of a Proactive Graduated Dose Adjustment Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	<ul style="list-style-type: none"> • GI cancer patients • Protocol under review • Expected activation: Fall 2025
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors	<ul style="list-style-type: none"> • Recruiting 408 AYAs • Protocol being prepared at ECOG-ACRIN • Expected start: Winter 2025

Did You Know?

Georgia Cancer Trial Finders (GCTF) is a free, statewide Georgia CORE resource that helps identify oncology clinical trials located in Georgia.

If you do not have a suitable trial available within your current research portfolio for your patient, GCTF can assist in determining whether other trials in Georgia may be available. By maintaining a network of research coordinators across the state, the GCTF Clinical Trials Navigator can connect you directly—via email—to sites actively conducting research, helping to save time and reduce back-and-forth communication.

In addition to NCORP trials, we encourage you to share your broader trial portfolio so we can refer patients who may be a fit for your studies. Trial portfolios and inquiries may be sent to navigator@georgiacore.org. Learn more at www.GeorgiaCancerInfo.org/TrialFinders and submit a patient referral here.

CLINICAL RESEARCH

NEWSLETTER DECEMBER 2025 VOLUME 1 | ISSUE 9

TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.

1. The primary goal of a Phase I oncology clinical trial is to:
 - A. Evaluate overall survival
 - B. Compare the investigational drug to standard of care
 - C. Determine safety, tolerability, and recommended dose
 - D. Assess quality of life outcomes
2. The Common Terminology Criteria for Adverse Events, commonly abbreviated as _____, is used to standardize the classification and grading of adverse events in oncology trials.
3. Which biomarker is most commonly associated with targeted therapy selection in non-small cell lung cancer (NSCLC)?
 - A. HER2
 - B. BRAF
 - C. EGFR
 - D. BRCA1

CLINICAL RESEARCH NEWSLETTER

DECEMBER 2025
 VOLUME 1 | ISSUE 9

Upcoming Research base Meetings*

Research Base	Date	Location
NRG	January 22-24, 2026	San Francisco, CA
SWOG	April 30-May 2, 2026	San Francisco, CA
	October 8-10, 2026	Chicago, IL
ECOG	May 5-7, 2026	Baltimore, MD
	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
UPCOMING ROUTINE AUDITS¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.

Site	Accural to date
NHCI	0
LCRP	3
NGMC	0
Navicent	0
JBACC	0
Harbin	0
Pearlman	2
Tift	0
Totals	5

The Georgia CORE Research team would like to wish you a Safe and Happy Holiday's and we will see you in 2026!